



Pat'd 03/07939  
14 JAN 2005



INVESTOR IN PEOPLE

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 23 OCT 2003	
WIPO	PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

**PRIORITY DOCUMENT**  
SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH  
RULE 17.1(a) OR (b)

Signed

*Stephen Hordley*

Dated

18 September 2003

**BEST AVAILABLE COPY**



**The  
Patent  
Office**

**1/77**

**Request for grant of a patent**

*(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)*

The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

**18 JUL 2002**

1. Your Reference	SAL/PG4871		
2. Patent application number <i>(The Patent office will fill in this part)</i>	0216729.4		
3. Full name, address and postcode of the or of each applicant <i>(underline all surnames)</i>	GLAXO GROUP LIMITED GLAXO WELLCOME HOUSE BERKELEY AVENUE GREENFORD MIDDLESEX UB6 ONN GB		
Patents ADP number <i>(if you know it)</i>			
If the applicant is a corporate body, give the country/state of its corporation	GB		
4 Title of the invention	Animal Models		
5 Name of your agent <i>(if you know one)</i>	STEPHANIE A. LEAROYD		
"Address for service" in the United Kingdom to which all correspondence should be sent <i>(including the postcode)</i>	GLAXOSMITHKLINE CORPORATE INTELLECTUAL PROPERTY 980 GREAT WEST ROAD BRENTFORD, MIDDLESEX TW8 9GS, GB		
Patents ADP number <i>(if you know it)</i>	8082071002		
6. If you are declaring priority from one or more earlier patent applications, give the country and date of filing of the or of each of these earlier applications and <i>(if you know it)</i> the or each application number	Country	Priority application number <i>(if you know it)</i>	Date of Filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant a patent required in support of this request? <i>(Answer yes if:</i> a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body.	YES		

See note (d))

9. Enter the number of sheets for any of the

**Patents Form 1/77**

Following items you are filing with this form.  
Do not count copies of the same document

Description	21 ✓
Claim(s)	5 ✓
Abstract	-
Drawing(s)	6 only
Sequence Listing	6 ✓

CF

10. If you are also filing any of the following,  
state how many against each item

**Priority Documents**

Translations of priority documents

Statement of inventorship and right  
to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination  
and search (*Patent Form 9/77*)

Request for substantive examination  
(*Patent Form 10/77*)

Any other documents  
(*please specify*)

11.

I/We request the grant of a patent on the basis of this application

*Stephanie A. Learoyd*

Signature **STEPHANIE A. LEAROYD 18 JULY 2002**  
**AGENT FOR THE APPLICANTS**

12. Name and daytime telephone number of  
person to contact in the United Kingdom

**KATHERINE EVANS**  
**01438 768611**

**Warning**

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication of communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patent Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been received

**Notes**

If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

Write your answers in capital letters using black ink or you may type them.

If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form

If you have answered "Yes" Patents Form 7/77 will need to be filed.

Once you have filled in the form you must remember to sign and date it.

For details of the fee and ways to pay please contact the Patent Office.

## Animal Models

### **Field of the Invention**

The present invention relates to a non-human animal model for screening potential agents for the treatment of human rhinovirus (HRV) infection, such as the common cold. The invention also relates to associated polynucleotide transgenes, constructs, vectors, cells and methods for testing and screening such potential drugs.

### **Background of the Invention**

Human rhinovirus (HRV) infections cause two thirds of upper respiratory tract infections (common colds) which are associated with enormous morbidity, absence from school and work and health care costs. Lower respiratory tract HRV infections are also associated with life threatening illnesses such as pneumonias in the immunosuppressed, acute exacerbations of asthma, ( Johnston, S.L., *Allergy* **53**,922-932 (1998) and other respiratory diseases such as chronic obstructive pulmonary disease (COPD; Seemungal, T., *et.al.*, *Am.J.Respir.Crit Care Med.* **164**,1618-1623, 2001). Asthma now affects up to 30% of children and 10-15% of adults in the westernised communities and HRV infection is implicated in the majority of acute exacerbations of the disease, (Johnston, S.L., *et.al.*, *BMJ*, **310**, 1225-1229, 1995). The overall morbidity and economic burden attributable to HRV is therefore considerable.

HRVs constitute the majority of the *rhinovirus* genus of the *Picornaviridae*. There are over 100 distinct serotypes of HRV and this has prevented the development of effective vaccines. A small animal model of HRV infection would be invaluable for testing potential anti rhinoviral compounds and for elucidating mechanisms of disease to generate new targets for development of therapies. However, there is no small animal model for HRV infection and *in vivo* research is restricted to large primate studies or studies in human volunteers.

A major obstacle to the development of small animal models of infection, such as murine models, is the host cell tropism of HRV. Approximately 10% of HRV serotypes make up the minor receptor group, which can use both the human and animal, such as murine, forms of low-density lipoprotein receptor (LDLr) to enter cells of either species. However, the remaining 90% of HRV's comprise the major receptor group and use human intercellular adhesion molecule-1 ( ICAM-1) to achieve cell attachment and entry (Greve, J.M., *et. al.*, *Cell*, **56**, 839-847, 1989; Staunton, *et. al.*, *Cell*, **56**, 849-853, 1989; Tommassini, J.E., *et.al.*, *Proc.Natl. Acad. Sci. USA* **86**, 4907-4911, 1989; Uncapher, C.R., *et. al.*, *Virology*, **180**, 814-817, 1991). These viruses do not appear to bind to non-human particularly murine ICAM-1 (e.g. Register, R.B., *et.al.*, *J.Virol.*, **65**, 6589-6596, 1991; Staunton, D.E., *et.al.*, *J.immunol.* **148**, 3271-3274, 1992) and therefore species specific restriction of HRV replication is implemented at the earliest stage in the infection cycle.

ICAM-1 (CD54) is involved in inflammatory functions mediated by leukocyte adhesion (Makgoba, M.W., *et.al.*, *Nature*, **331**, 86-88, 1988). It belongs to the immunoglobulin supergene family and both human and non-human e.g. murine

ICAM-1 have five homologous 'Ig-like' extracellular domains (D1 to D5), a transmembrane domain and a short C-terminal cytoplasmic domain. The two amino-terminal domains of human ICAM-1 (D1 and D2) have been shown to bind to major group HRV's and to confer this ability on a murine ICAM-1 polypeptide (*Register, R.B., et al, 1991; J. Virol. 65, 6589-6596; Staunton, D.E., et.al., Cell, 61, 243-254, 1990 Bella et al., Proc.Natl.Acad.Sci.USA, 95:4140, 1998; Staunton, D.E., et.al., J.Immunol. 148, 3271-3274, 1992*). The transmembrane and cytoplasmic domains of ICAM-1 are not thought to be required for internalization of major group HRVs but may be required for normal ICAM-1 intracellular signalling functions (Staunton, D.E., *et.al., J.Immunol. 148, 3271-3274, 1992*).

Despite increased knowledge of HRV and mechanisms of infection, there remains a critical need to develop a small animal model of HRV infection.

### Summary of the Invention

The present inventors have generated a transgenic animal model of HRV respiratory tract infection. They have found that the use of a construct comprising a polynucleotide sequence which encodes human ICAM-1 domains D1 and D2 results in a transgenic non-human animal that expresses a ICAM-1 polypeptide which is capable of supporting binding and infection of major group HRV. Furthermore, the transgenic non-human animals of the invention are particularly capable of expressing the ICAM-1 polypeptide in cells and tissues of the respiratory tract.

Accordingly, the present invention provides a transgenic non-human animal whose genome comprises a polynucleotide encoding human ICAM-1 domains D1 and D2. The transgenic non-human animal of the invention is capable of expressing a ICAM-1 polypeptide which comprises human ICAM-1 domains D1 and D2.

In one embodiment, the present invention provides a transgenic non-human animal whose genome comprises a polynucleotide encoding human ICAM-1 domains D1 and D2 and one or more of host non-human animal ICAM-1 domains D3, D4 and D5 and most preferably a polynucleotide encoding human ICAM-1 domains D1 and D2 and each of host non-human animal ICAM-1 domains D3, D4 and D5. Additionally the polynucleotide incorporated into the animal genome may encode host non-human animal ICAM-1 transmembrane and/or cytoplasmic domains. The transgenic animal is capable of expressing a chimaeric ICAM-1 polypeptide which comprises human ICAM-1 domains D1 and D2 and one or more of host non-human animal ICAM-1 domains D3, D4 and D5, and preferably a chimaeric ICAM-1 polypeptide which comprises human ICAM-1 domains D1 and D2 and each of host non-human animal ICAM-1 domains D3, D4 and D5. The chimaeric ICAM-1 polypeptide may further comprise host non-human animal transmembrane and/or cytoplasmic domains of ICAM-1.

The transgenic non-human animal of the invention provides a small animal model of HRV respiratory tract infection. Such a model provides an extremely useful tool for identifying and evaluating (with regard to efficacy and safety) therapeutic agents e.g. chemical compounds which inhibit or otherwise modulate HRV binding,

internalisation and/or replication, and furthermore would assist in further defining mechanisms of viral immunopathology and evaluating potential therapeutic targets. Additionally, such a model could usefully be combined with existing small animal models of asthma and COPD to study the role of viral infection in the exacerbation of airway disease.

**Brief Description of the Sequence Listings and Figures:**

- 10 SEQ ID No:1 provides the polynucleotide (DNA) sequence encoding human ICAM-1 polypeptide
- SEQ ID No:2 provides the polynucleotide (DNA) sequence encoding human ICAM-1 domain D1
- 15 SEQ ID No:3 provides the polynucleotide (DNA) sequence encoding human ICAM-1 domain D2
- SEQ ID No:4 provides the polypeptide (amino acid) sequence of human ICAM-1
- 20 SEQ ID No:5 provides the polypeptide (amino acid) sequence of human ICAM-1 domain D1
- SEQ ID No:6 provides the polypeptide (amino acid) sequence of human ICAM-1 domain D2
- 25 SEQ ID No:7 provides the polynucleotide (DNA) sequence encoding murine ICAM-1 polypeptide
- SEQ ID No:8 provides the polynucleotide (DNA) sequence encoding murine ICAM-1 domain D3
- 30 SEQ ID No:9 provides the polynucleotide (DNA) sequence encoding murine ICAM-1 domain D4
- SEQ ID No:10 provides the polynucleotide (DNA) sequence encoding murine ICAM-1 domain D5
- 35 SEQ ID No:11 provides the polypeptide (amino acid) sequence of murine ICAM-1 domain D3
- 40 SEQ ID No:12 provides the polypeptide (amino acid) sequence of murine ICAM-1 domain D4
-

SEQ ID No:13 provides the polypeptide (amino acid) sequence of murine ICAM-1 domain D5

5 SEQ ID No:14 provides the nucleotide sequence (DNA) encoding a human/mouse chimaeric ICAM-1 polypeptide

SEQ ID No:15 provides the polypeptide (amino acid) sequence of a human /mouse chimaeric ICAM-1 polypeptide

10 SEQ ID No:16 provides the nucleotide sequence (DNA) encoding rat ICAM-1 polypeptide

15 Figure 1: This shows the plasmid vector pcDNA3.1+ containing a human-mouse chimaeric ICAM-1 cDNA

Figure 2: This demonstrates that murine respiratory epithelial cells (LA4) transfected with a human-mouse chimaeric ICAM-1 DNA express chimaeric ICAM-1

20 Figure 3: This demonstrates that murine respiratory epithelial cells (LA4) expressing chimaeric ICAM-1 are susceptible to infection with and can support the replication of major group HRV

25 Figure 4: This demonstrates the replication of major group HRV in murine respiratory epithelial cells

Figure 5: This shows details of human ICAM-1 peptides used for generation of rabbit anti-human ICAM-1 polyclonal antibodies

30 Figure 6: This demonstrates the expression of chimaeric ICAM-1 in airways tissue of transgenic mice

#### Detailed description of the Invention

35 The present invention provides a transgenic non-human animal whose genome comprises a polynucleotide encoding a ICAM-1 polypeptide comprising human ICAM-1 domains D1 and D2, preferably human ICAM-1 domains D1 and D2 and one or more of host non-human animal ICAM-1 domains D3, D4 and D5, and most preferably all three host non-human animal ICAM-1 domains D3,D4 and D5. The ICAM-1 polypeptide encoded by the polynucleotide incorporated into the non-  
40 human animal genome may further comprise host non-human animal ICAM-1 transmembrane and/or cytoplasmic domains. The transgenic non-human animal is capable of expressing a chimaeric ICAM-1 polypeptide. The expressed ICAM-1 polypeptide such as a chimaeric ICAM-1 polypeptide is at least capable of supporting

binding and infection of major group HRV and is expressed particularly in cells and/or tissues of the respiratory tract or airways. Preferably, the ICAM-1 polypeptide has the basic biological functionality of native ICAM-1 of the host animal. Such basic biological functionality would be appreciated by a person skilled in the art to include  
5 without limitation any of the following cell-cell adhesion in inflammatory and immune systems, where ICAM-1 mediates responses such as leukocyte attachment to endothelium and migration towards sites of inflammation. It may also include, T and B cell activation, thymocyte development, and T-cell effector function. In addition, ICAM-1 functions in cell-cell signalling, for example in T-cell activation as a  
10 costimulatory molecule and as an inducer of apoptosis.

The polynucleotide comprised in the genome of the transgenic non-human animal may comprise any number of nucleic acid sequences. For example, the polynucleotide may comprise one or more nucleic acid sequences encoding human  
15 domains D1 and D2 and/or one or more nucleic acid sequences encoding non-human domains D3, D4 and D5. In all aspects, however, the polynucleotide preferably encodes a ICAM-1 polypeptide e.g. chimaeric ICAM-1 which is capable of being expressed in the non-human animal, particularly in airways tissues.

The polynucleotide comprised in the genome of the transgenic non-human  
20 animal includes wild type forms and any modified forms provided the expressed chimaeric ICAM-1 is capable of binding and supporting infection with major group HRV. Modified polynucleotides include without limitation those which have one or more nucleotide substitutions, deletions, insertions or inversions.

In a preferred aspect the transgenic non-human animal is a mammal,  
25 preferably a rodent such as a mouse, rat or guinea pig, and more preferably a mouse. Thus, in a particularly preferred embodiment the chimaeric ICAM-1 polypeptide comprises human ICAM-1 domains D1 and D2 and one or more of murine ICAM-1 domains D3, D4 and D5, especially human ICAM-1 domains D1 and D2 and each of murine ICAM-1 domains D3, D4 and D5.

30 The polynucleotide encoding the ICAM-1 polypeptide comprised in the genome of a transgenic non-human animal of the invention may comprise one or more of the following polynucleotide sequences:

- 35 (a) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:2;
- (b) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:3;
- 40 (c) a polynucleotide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:5;



- (d) a polynucleotide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:6;
- (e) a polynucleotide fragment of SEQ ID No:1 (or a sequence with at least 90%, or more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) encoding human ICAM-1 domains D1 and D2; and
- (f) a polynucleotide sequence encoding a polypeptide fragment of SEQ ID No:4 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) comprising human ICAM-1 domains D1 and D2.

When the transgenic non-human animal is a mouse, the polynucleotide encoding the chimaeric ICAM-1 comprised in the mouse genome may comprise in addition to the human nucleotide sequences defined above one or more of the following murine polynucleotide sequences:

- (a) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:8;
- (b) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:9;
- (c) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99%, or 100% identity to the polynucleotide sequence of SEQ ID No:10;
- (d) a polynucleotide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:11;
- (e) a polynucleotide sequence encoding a polypeptide sequence having at least 90% or more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:12;
- (f) A polypeptide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99%, or 100% identity to the polypeptide sequence of SEQ ID No:13; and
- (g) a polynucleotide fragment of SEQ ID No:7 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) encoding one or more of murine ICAM-1 domains D3, D4 and D5.

In one particular embodiment of a transgenic mouse of the invention, the polynucleotide encoding a chimaeric ICAM-1 polypeptide comprised in the mouse genome comprises one or more of the following polynucleotide sequences:

- (a) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:14.
- (b) a polynucleotide encoding a polypeptide having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:15.

When the transgenic non-human animal is a rat, the polynucleotide encoding the chimaeric ICAM-1 comprised in the rat genome may comprise a polynucleotide sequence comprising a fragment of SEQ ID No:16 (or a sequence at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) encoding one or more of rat ICAM-1 domains D3, D4 and D5.

The ICAM-1 polypeptide expressed by the non-human transgenic animal may comprise one or more of the following polypeptide sequences:

- (a) a polypeptide fragment of SEQ ID No:4 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) comprising human ICAM-1 domains D1 and D2;
- (b) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:5; and
- (c) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:6.

The chimaeric ICAM-1 polypeptide encoded by the polynucleotide incorporated into the genome of a non-human animal may further comprise a polypeptide comprising one or more of host non-human ICAM-1 domains D3, D4 and D5, and preferably all three.

When the transgenic non-human animal is a mouse the human/murine chimaeric ICAM-1 polypeptide encoded by the polynucleotide incorporated into the mouse genome may comprise one or more of the following polypeptide sequences:

- (a) a polypeptide fragment of SEQ ID No:7 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) comprising one or more of murine ICAM-1 domains D3, D4 and D5;
- (b) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:11;
- (c) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:12; and

- (d) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:13.

5 In a preferred embodiment, the chimaeric ICAM-1 polypeptide comprises human ICAM-1 domains D1 and D2 and murine ICAM-1 domains D3, D4 and D5. Thus in a particular embodiment, the human/murine chimaeric ICAM-1 polypeptide comprises:

- 10 (a) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:15.

The chimaeric ICAM-1 polypeptide is expressed in the cells and tissues of the non-human transgenic animal and is particularly expressed in the cells and/or tissues  
15 of the respiratory tract or airways, especially respiratory tract epithelial cells.

The present invention relies on the use of a nucleic acid construct or transgene to generate transgenic animals of the present invention. The construct or transgene comprises a polynucleotide encoding human ICAM-1 domains D1 and D2, one or more of host non-human (such as rat or mouse) ICAM-1 domains D3, D4 and  
20 D5 as defined herein (and optionally host non-human ICAM-1 transmembrane and/or cytoplasmic domains), and a suitable regulatory sequence such as a promoter which can be expressed in a broad range of different cell types including cells and/or tissues of the respiratory tract, for example, a CMV or SV40 promoter. Also suitable are promoters with an airways-restricted pattern of expression, such as the human  
25 surfactant protein C (SPC) or Clara cell 10-kDa secretory protein (CC10) promoter.

The assembly of the transgenic construct follows standard cloning techniques, that are well known in the art (for example see *Sambrook, et al., Molecular Cloning: A laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1989)*).

30 The polynucleotide encoding chimaeric ICAM-1 may be constructed from cDNA or genomic DNA of ICAM-1 from a human and non-human animal. If it is cDNA, the cDNA can be prepared *de novo* by e.g reverse transcriptase PCR (RT-PCR) from an mRNA extracted from a relevant tissue of a human and of a non-human animal. Alternatively, the cDNA may be excised from vectors containing the  
35 full length cDNAs of human or murine ICAM-1. The chimaeric cDNA, together with the desired regulatory sequence and any other desired components such as artificial introns, polyadenylation sequences, reporter genes and genes which will allow antibiotic selection in both prokaryotic (e.g bacterial) and mammalian cell lines can then be inserted into a cloning vector by restriction digest and ligation. Suitable  
40 vectors such as plasmids for the assembly of transgenes are those which provide for acceptable yields of DNA. Typical examples could include, pCDNA 3.1, pBlueScript, or other plasmid cloning vectors having a medium to high copy number in routinely used strains of *Escherichia coli*.

The regulatory sequences, such as promoters, are operably linked to the coding sequence of the chimaeric ICAM-1 encoding polynucleotide or polynucleotides in a manner that will permit expression of the polynucleotide. There may or may not be intervening sequences between the chimaeric ICAM-1 encoding polynucleotide(s) and the promoter, provided that the promoter directs expression of the desired polynucleotides appropriately.

Methods of linking regulatory sequences to cDNAs to facilitate their expression are widely known in the art. Such methods include without limitation directly ligating a nucleic acid sequence comprising a regulatory sequence to the coding region of the desired polynucleotide in this case the polynucleotide encoding chimaeric ICAM-1. Additional nucleic acid sequences may be included that modulate expression and include enhancer elements, artificial introns and others.

Preferably prior to the introduction of the chimaeric transgene into the host cell, the vector portions are removed by restriction enzyme digestion, for example by using restriction sites in the vector that flank the transgene. Thus the genetic material introduced into a host cell will preferably comprise the polynucleotide encoding chimaeric ICAM-1 as defined herein and the regulatory sequences to which it has been operably linked together with other potential components of the transgene such as polyadenylation sequences, reporter genes and genes which will allow antibiotic selection in the cell.

The present invention also includes any cells cultured from the transgenic non-human animals of the invention. The cells are cultured in-vitro. The genome of the cells thus comprise the construct or transgene of the invention. Preferred cells are cells of the respiratory tract implicated or otherwise involved in HRV infection such as respiratory epithelial cells.

Cells cultured in-vitro from a transgenic animal may be prepared by any suitable method. The cells are typically rodent such as mouse or rat, and most preferably mouse. Cultures of respiratory cells such as respiratory epithelial cells can therefore be provided and used for in-vitro experiments such as in-vitro screening of test agents that may modulate HRV binding and infection.

The invention also includes any cell transformed or transfected preferably stably transfected with a polynucleotide encoding chimaeric ICAM-1 as defined herein. Such cells include bacterial and yeast cells used to replicate a vector comprising the chimaeric ICAM-1 encoding polynucleotide, non-human cells such as respiratory epithelial cells to generate a cell line useful for relevant in-vitro studies and stem cells that are used to generate the non-human transgenic animals of the invention. The non-human transgenic animals of the invention may be generated by the use of any suitable protocol known in the art such as:

- introducing the desired polynucleotide into a suitable cell
- allowing the cell to develop into a transgenic animal
- optionally, breeding the animal true.

There are a number of techniques that permit the introduction of genetic material, such as a transgene, into the germline. A commonly used, protocol comprises direct injection of the transgene into the male pronucleus of the fertilised egg (Hogan et al., *Manipulating the mouse embryo* (A laboratory manual) Second edition, CSHL Press 1994), resulting in the random integration into one locus of a  
5 varying number of copies, usually in a head to tail array (Costantini and Lacy, *Nature* 294, 92, 1981). The injected eggs are then re-transferred into the uteri of pseudo-pregnant recipient mothers. Some of the resulting offspring may have one or several copies of the transgene integrated into their genomes, usually in one integration site.  
10 These "founder" animals are then bred to establish transgenic lines and to back-cross into the genetic background of choice. It is convenient to have the transgene insertion on both chromosomes (homozygosity) as this obviates the need for repeated genotyping in the course of routine mouse husbandry.

Alternatively, for the production of transgenic mice, transgenes can be  
15 introduced via embryonic stem (ES) cells, using electroporation, retroviral vectors or lipofection for gene transfer. This is followed by the random insertion into the genome of the pluripotent embryonic stem (ES) cells, followed by the production of chimaeric mice and subsequent germline transmission. Transgenes of up to several hundred kilobases of rodent DNA have been used to produce transgenic mice in  
20 this manner (for example Choi et al., *Nature Genet.* 4, 117-123 (1993); Strauss et al., *Science* 259, 1904-07 (1993)). The latter approach can be tailored such that the transgene is inserted into a pre-determined locus (non-randomly, for example ROSA26 or HPRT) that supports ubiquitous as well as tissue specific expression of the transgene (Vivian et al., *BioTechniques* 27, 154-162 (1999)). The transgenic  
25 animals can be subsequently tested to ensure the required genotypic change has been effected, in any suitable fashion. This can be done by, for example, detecting the presence of the transgene by PCR with specific primers, or by Southern blotting of tail DNA with a specific probe. Testing for homozygosity of the transgene insertion may be carried out using quantitative Southern blotting to detect a twofold difference  
30 in signal strength between hetero- and homozygous transgenic animals. Once the desired genotype has been confirmed the transgenic animal line can be subjected to various tests to determine the phenotype. The tests involved in this phenotypic characterisation depend on what genotypic change has been effected, and may include, for example, morphological, biochemical and behavioural studies. The  
35 transgenic animals of the present invention demonstrate expression of chimaeric ICAM-1 as defined herein and hence the ability to support binding, internalisation and infection of major group HRV.

Expression of a chimaeric ICAM-1 polypeptide can be established at the RNA or protein level e.g. by obtaining the corresponding mRNA or protein from the animal  
40 and analysing expression. Infection by major group HRV can be determined by for example observing cytopathic effects in relevant cells such as respiratory epithelial cells. Infection may also be determined by virus plaque assay using lavage samples  
obtained from the upper or lower respiratory airways of the infected animal.

The use of non-human animal models with altered expression of more than one gene can provide important insights into the genetic basis of particular diseases for example asthma and other inflammatory respiratory disorders. Consequently the interbreeding of the transgenic non-human animals of the present invention with non-human animal models which overexpress, underexpress or have an otherwise altered expression of a different gene may produce superior animal models of diseases such as asthma. In particular, such an approach could be used to develop a superior animal model in which the role of viral infection e.g. HRV infection in the exacerbation of respiratory disorders such as asthma and COPD could be studied.

Additionally, the transgenic non-human animal model of the present invention can be used to study the role of HRV infection in exacerbation of asthma or other airways disease in suitable animal models. In the case of asthma, the animal is "primed" and sensitised by repeated injection of ovalbumin over time, followed by subsequent exposure ("challenge") of particulate albumin in the airways, as described (Lloyd, C.M., *et.al.*, *Advances in Immunology*. 77, 263-95, 2001). Measurements of lung function would indicate the severity of the disease in the presence or absence of other exacerbating factors such as HRV.

Cells and animals of the present invention may also be used to identify and test the efficacy of potential therapeutic agents for the treatment of conditions associated with HRV infection. Potential therapeutic agents may inhibit (antagonise) major group HRV binding to the chimaeric ICAM-1 expressed by the transgenic animals of the invention, or inhibit (antagonise) viral replication.

A method of identifying a therapeutic agent for the treatment of conditions associated with or exacerbated by major group HRV infection can therefore be provided, comprising:

- administering to a transgenic animal of the invention a test substance and
- determining whether the test substance (i) prevents or delays the onset of the condition or (ii) treats or alleviates the condition.

Conditions associated with major group HRV infection include the common cold and conditions exacerbated by major group HRV infection include asthma, COPD and other respiratory disorders. Thus the efficacy of a test substance may be determined by analysing cellular e.g. cytopathic effects, plaque assay and/or physiological e.g. exacerbation of typical adverse respiratory symptoms changes following HRV infection.

The invention further provides a method of identifying a therapeutic agent for the treatment of a condition associated with or exacerbated by major group HRV infection, comprising:

- contacting a test substance with a cell of the invention
- determining whether the test substance (i) prevents or delays the onset of cellular changes associated with the condition or (ii) causes a decrease in any of the cellular changes associated with the condition.

Suitable test substances which may be tested in the above methods include antibody products (for example, monoclonal and polyclonal antibodies, single chain antibodies, chimaeric antibodies and CDR grafted antibodies). Furthermore, combinatorial libraries, defined chemical identities, small molecules, peptide and peptide mimetics, oligonucleotides and natural product libraries, such as display libraries (e.g. phage display libraries) may also be tested. Preferably, the test substances may be chemical compounds. Batches of the test substances may be used in an initial screen of, for example, ten substances per reaction, and the substances of batches which show inhibition tested individually.

Agents identified in the screening methods of the invention may be used to prevent or treat the conditions discussed above. The clinical outcome of a patient suffering from such a disease can therefore be improved by administration of such a product.

The formulation of the product for use in preventing or treating any condition will depend upon factors such as the nature of the agent identified and the disease to be prevented or treated. Typically the agent is formulated for use with a pharmaceutically acceptable carrier or diluent. For example it may be formulated for inhaled, intracranial, parenteral, intravenous, intramuscular, subcutaneous, transdermal or oral administration but particularly for inhaled and oral administration.

A physician will be able to determine the required route of administration for each particular patient.

The dose of product may be determined according to various parameters, especially according to the substance used; the age, weight and condition of the patient to be treated; the route of administration; and the required regimen. A suitable dose may however be from 0.1 to 100 mg/kg body weight such as 1 to 40 mg/kg body weight. Again, a physician will be able to determine the required route of administration and dosage for any particular patient.

The following definitions are provided to facilitate understanding of certain terms used frequently herein before.

A "transgene" comprises a polynucleotide, isolated from nature, which has been manipulated *in-vitro* and can then subsequently be introduced into the genome of the same or different species in either the native or modified forms, such that it is stably and heritably maintained in that genome. A "Chimaeric transgene" comprises a polynucleotide created or derived from both a human and a non-human animal polynucleotide sequence, which has been manipulated *in-vitro* and can then subsequently be introduced into the genome of the host non-human animal in either the native or modified forms, such that it is stably and heritably maintained in that genome. In either case native forms include unmodified polynucleotides isolated from a source different to that into which it is subsequently introduced. Modified polynucleotides include those which have one or more nucleotide substitutions, deletions, insertions or inversions. Native or modified polynucleotides may be operably linked to a heterologous promoter, or other regulatory sequence, from a different gene within the same species or from a gene in a different species. A

polynucleotide is operably linked to a regulatory sequence when, for example, it is placed under the transcriptional control of said regulatory sequence. The polynucleotide may or may not encode a polypeptide, and if a polypeptide is expressed from the polynucleotide, said polypeptide may or may not be full-length relative to that encoded by the original polynucleotide isolated. The term transgene is generally used to refer to the polynucleotide and the regulatory sequences to which it is operably linked but may refer to the polynucleotide minus any regulatory sequences.

An organism into which a transgene has been introduced is termed a "transgenic" organism.

"Regulatory sequences" refer to DNA or RNA polynucleotide sequences, which are usually non-coding, that are involved in the regulation of transcriptional activity or tissue-specific enhancement or silencing of gene transcription. Such regulatory sequences include promoters and enhancers.

"Identity" as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences. In the art, "identity" also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences. "Identity" and "similarity" can be readily calculated by known methods, including but not limited to those described in (*Computational Molecular Biology*, Lesk, A.M., ed., Oxford University Press, New York, 1988; *Biocomputing: Informatics and Genome Projects*, Smith, D.W., ed., Academic Press, New York, 1993; *Computer Analysis of Sequence Data*, Part I, Griffin, A.M., and Griffin, H.G., eds., Humana Press, New Jersey, 1994; *Sequence Analysis in Molecular Biology*, von Heinje, G., Academic Press, 1987; and *Sequence Analysis Primer*, Gribskov, M. and Devereux, J., eds., M Stockton Press, New York, 1991; and Carillo, H., and Lipman, D., *SIAM J. Applied Math.*, 48: 1073 (1988). Preferred methods to determine identity are designed to give the largest match between the sequences tested. Methods to determine identity and similarity are codified in publicly available computer programs. Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., *Nucleic Acids Research* 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., *J. Molec. Biol.* 215: 403-410 (1990)). The BLAST X program is publicly available from NCBI and other sources (*BLAST Manual*, Altschul, S., et al., NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al., *J. Mol. Biol.* 215: 403-410 (1990)). The well known Smith Waterman algorithm may also be used to determine identity.

Preferred parameters for polypeptide sequence comparison include the following:

1) Algorithm: Needleman and Wunsch, *J. Mol Biol.* 48: 443-453 (1970)  
Comparison matrix: BLOSSUM62 from Hentikoff and Hentikoff, *Proc. Natl. Acad. Sci. USA.* 89:10915-10919 (1992)

Gap Penalty: 12



Gap Length Penalty: 4

A program useful with these parameters is publicly available as the "gap" program from Genetics Computer Group, Madison WI. The aforementioned parameters are the default parameters for peptide comparisons (along with no penalty for end gaps).

Preferred parameters for polynucleotide comparison include the following:

1) Algorithm: Needleman and Wunsch, J. Mol Biol. 48: 443-453 (1970)

Comparison matrix: matches = +10, mismatch = 0

Gap Penalty: 50

Gap Length Penalty: 3

Available as: The "gap" program from Genetics Computer Group, Madison WI. These are the default parameters for nucleic acid comparisons.

By way of example, a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:1, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence. Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence. The number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO:1 by the numerical percent of the respective percent identity (divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO:1, or:

$$n_n \leq x_n - (x_n \cdot y),$$

wherein  $n_n$  is the number of nucleotide alterations,  $x_n$  is the total number of nucleotides in SEQ ID NO:1, and  $y$  is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%, etc., and wherein any non-integer product of  $x_n$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_n$ . Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:4 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.

Similarly, a polypeptide sequence referred to herein may be identical to the reference sequence of SEQ ID NO:4, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%. Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or

more contiguous groups within the reference sequence. The number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:4 by the numerical percent of the respective percent identity (divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:4, or:

$$n_a \leq x_a - (x_a \cdot y),$$

wherein  $n_a$  is the number of amino acid alterations,  $x_a$  is the total number of amino acids in SEQ ID NO:4, and  $y$  is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non-integer product of  $x_a$  and  $y$  is rounded down to the nearest integer prior to subtracting it from  $x_a$ .

The invention is now illustrated by reference to the following Examples.

### Examples

#### 1. Generation of a Functional Chimaeric Human/Murine ICAM-1 cDNA.

The engineering of a chimaeric ICAM-1 cDNA was facilitated by a conserved *Bgl* I restriction site located between domains 2 and 3 of both the human and murine ORFs (Seq ID no:14). Plasmids pCDM8-HuICAM-1 and pBS-Mo-ICAM-1 (Siu, G., *et.al.*, *J.Immunol.* **143**, 3813-3820, 1989) containing the full -length cDNAs of human and murine ICAM-1, respectively, were provided by A.Craig (University of Oxford) and D.Haskard (Royal Postgraduate Medical School, London) respectively. *Hind* III to *Not* I fragments for each ORF were subcloned into pCDNA3.1 (+) (Invitrogen). The *Hind* III to *Bgl* I fragment containing murine ICAM-1 domains 1 & 2 was replaced by a *Hind* III-*Bgl* I fragment containing human ICAM-1 domains 1 & 2 to create pHu/MuICAM-1 (as shown in Figure 1). Reading -frame integrity was confirmed by [<sup>35</sup>S] methionine- labelled *in vitro* translation, using a reticulocyte lysate system (Promega) followed by SDS-PAGE and autoradiography. There was no difference in the apparent size of the recombinant protein, compared to that of human or murine ICAM-1.

To further confirm the integrity and functionality of the chimaeric ICAM-1 in pHu/MuICAM-1, it was also expressed in the monkey kidney cell line Cos7, which is otherwise non permissive for entry of major group HRV. The ability of the chimaeric molecule to support binding, cell entry and replication of major group virus was confirmed by challenge of cells with HRV16 and immunoprecipitation of virus-specific proteins from lysates. This was followed by growth of live virus from supernatants of transfected but not mock- transfected cells.

Domain replacement had no effect on the apparent size of the protein when translated *in vitro* and visualized by SDS PAGE and preliminary *in vitro* data suggest that intracellular signalling through the chimaeric molecule is broadly equivalent to that through murine ICAM-1.

## 2. Generation of stable cell lines expressing Chimaeric Hu/MuICAM-1

Subconfluent monolayers of murine respiratory epithelial cells (LA-4) were transfected with pHu/MuICAM-1 cDNA using Lipofectin (Life Technologies) according to the manufacturer's recommendations. Stably transfected LA-4 cells were selected in the presence of the antibiotic G418 ~600µg/ml with subsequent maintenance at 250µg/ml.

The ability of these cells to express chimaeric ICAM-1 and to support major group HRV replication was examined.

### 2.1 Expression of Chimaeric ICAM-1 in mouse respiratory epithelial cells

Monolayers of recombinant LA-4 cells in multi-well plates were fixed with 3% paraformaldehyde in PBS, washed with PBS and incubated with an anti-human ICAM-1 monoclonal antibody 15.2 (Serotec) at 5 µg/mL in PBS. After washing, cells were incubated with FITC-conjugated polyclonal antibodies raised against mouse immunoglobulins (Dako) at a dilution of 1:2000 in PBS. Fluorescent photomicroscopy was carried out using an Olympus UV microscope. Immunofluorescence data confirmed expression of chimaeric ICAM-1 in recombinant LA-4 cells.

Further confirmation of the expression of chimaeric ICAM-1 in recombinant LA-4 cells was provided by flow cytometric (FACS) analysis of the transfected cell line with a species specific antibody for human ICAM-1. For the analysis, approximately  $2 \times 10^5$  cells were washed in PBS supplemented with 2% FCS and 0.01% NaN<sub>3</sub> and incubated with 10 µl of anti-ICAM-1 R-phycoerythrin (PE)-conjugated monoclonal antibody HA58 or its isotype control (Becton Dickinson) at 4°C for 30 min. Cells were washed three times, resuspended in PBS and analysed for fluorescence by single color flow cytometry using a Beckman Coulter EPICS ELITE™. The flow cytometry was used to compare the expression of ICAM-1 in the stably transfected cells (LA4-Hu/MuICAM-1), the LA4 parental cell line, a human bronchial epithelial cell line (16HBE) and the human cell line Ohio HeLa, used for routine propagation of HRV's. The analysis (Figure 2) shows that recombinant LA-4-Hu/Mu ICAM-1 cells express chimaeric ICAM-1 at similar levels as human ICAM-1 in 16 HBE and Ohio HeLa cells

### 2.2 Major group HRV infection of mouse respiratory epithelial cells

LA-4 parental (control) and stably transfected (LA4-ICAM-1) cells were challenged with major group HRV16 at high (5) and low (0.1) MOI. The appearance of the cells and virus titre of cell extracts were recorded at various time points post-infection. Challenge with HRV16 induced no cytopathic effect (CPE) in the LA-4 control cells (Figure 3). Furthermore, after inoculation of these cells with HRV16 virus titres declined (Figure 4) at the same rate as that observed for the decay of virus in medium lacking cells. This further confirmed the inability of these cells to support the replication of major group HRV.

However, after inoculation of LA-4-Hu/Mu ICAM-1 cells with HRV16, the cells developed cytopathic effects (CPE) (Figure 3) and supported viral replication judged by rising viral titres as measured in a virus plaque assay shown in Figure 4. Major group HRV16 replicated only in those murine respiratory epithelial cells expressing the chimaeric ICAM-1, demonstrating that expression of the correct ICAM-1 molecule capable of virus binding is both necessary and sufficient for efficient major group HRV infection of these cells.

### 3. Production of Transgenic Animals expressing Chimaeric ICAM-1

Mice, transgenic for the Hu/Mu chimaeric ICAM-1 construct, were generated using the process of ES -cell mediated transgenesis, as described below:

#### 3.1 Transgene Preparation

25 µg microgrammes of pHu/Mu ICAM-1 (see Figure 1, ) were digested with the Sal1 restriction endonuclease, which cuts at base pair (bp) positions 32 and 5133 on the plasmid, to yield 5101 bp and 2222 bp fragments respectively. Digestion was confirmed by agarose gel electrophoresis, and the 5101 bp fragment, containing the CMV promoter, chimaeric Hu/Mu ICAM, bovine growth hormone poly adenylation sequence (bGHpA) and the SV40 promoter, Neo resistance gene, SV40polyA expression cassettes, was purified using a Qiaquick™ kit (Promega). The DNA was precipitated, washed and the pellet resuspended in 25 µL phosphate -buffered saline (PBS) solution, according to standard methodologies (Maniatis et. al., 1982, *Molecular Cloning. A Laboratory Manual*, Published by Cold Spring Harbor, Laboratory Press, NY.)

#### 3.2 Culture and Generation of recombinant Embryonic Stem Cell (ES) cell lines

HM-1 embryonic stem cells (Magain M., McWhir, J. and Melton, D., in *Nucleic Acids Res.* 20 (14) 3795, 1992), a feeder- independent ES cell -line derived from the 129P2 / Ola Hsd mouse, were used in this study. The cells were routinely cultured in "ES cell medium"; BHK21 (Glasgow's medium, GIBCO) supplemented with 0.1mM non -essential amino acids (100X stock, Gibco Cat. No320-1140AG), 1mM sodium pyruvate (100X stock, Gibco Cat.320-1360AG),  $10^{-6}$ M  $\beta$ -Mercaptoethanol (100X stock stored at -20°C, Sigma Cat.No.600564AG), 50 µgml<sup>-1</sup> Gentamicin (50 mg ml<sup>-1</sup> stock, Gibco Cat. No. 15750-045), Lif ESGRO™ ( $10^7$  Units ml<sup>-1</sup> stock, Chemicon International, Cat. No. ESG1107) and 10% Foetal Calf Serum (FCS, Tissue Culture Services, Buckingham, UK). Once prepared, the medium was filtered through a 0.2µ filter (type CA, Nalgene). Culture dishes were treated for 15 minutes prior to use, with 0.1% gelatin (Sigma) in Phosphate Buffered Saline solution (PBS, NaCl 8.0g, KCl 0.2g, KH<sub>2</sub>PO<sub>4</sub> 0.2g and Na<sub>2</sub>KPO<sub>4</sub> 1.15g in 1 litre at pH7.2). Cells were grown in the absence of mouse embryonic fibroblast feeder cells at 37°C and in an atmosphere of 95% humidity, 5%CO<sub>2</sub>. For routine maintenance, the cells were passaged every 3-4 days and replated on gelatinised dishes.

To create stable, recombinant ES cell lines, approximately  $2 \times 10^7$  cells in 0.8ml PBS were mixed with 25 $\mu$ g of linear pHu/Mu ICAM-1 (as described above) in a 0.4cm electroporation cuvette (BioRad) and electroporated at 500 $\mu$ F, 260Volts at room temperature. Following electroporation cells were plated at different densities on 5 x 10cm cell culture dishes (Nunc). After 24 hours the cells were washed and fed with new medium and then at 48hours, placed under positive selection (G418 antibiotic at 300  $\mu$ g ml<sup>-1</sup>). Cells were washed and fed every two days with fresh medium containing antibiotic. Between days 3-10, non-resistant cells died, with the subsequent appearance of colonies of G418 resistant clones from around days 8 - 12.

To expand the resistant clones, individual G418 -resistant colonies were "picked-off" from the 10cm dishes using a sterile p20 pipette and tip (Gilson) set at 10 $\mu$ l. The colony was picked into a 50 $\mu$ l droplet of Trypsin-EDTA (Cat. No. 043-05300M), in a sterile petri dish, pipetted up and down 2-3 times and subsequently transferred to 2ml of fresh ES cell medium plus antibiotic in a single well of a 24 well plate. In this manner, 48 G418 resistant clones were picked and expanded into individual wells of two 24-well plates. After approximately 10-14 days, when the colonies on each 24 -well plate became confluent, each well was passed into two single wells on two 24 well plates, thereby creating two identical wells each on a separate plate. The cells were again allowed to grow to near confluency and one duplicate plate (the "Master"), was frozen down, whilst the other (the "Analysis" plate) was used to provide cells for DNA preparation and analysis (See below). For freezing, the media in each well of the Master plate was aspirated and replaced with 300 $\mu$ l of freezing mix (70% ES cell media, 20% Foetal Calf Serum, 10% cell culture grade DMSO), the plate placed in an insulated polystyrene box and allowed to cool gradually to -70°C. Subsequently, the plate was transferred to a -135°C freezer for storage whilst DNA from the Analysis plate was being prepared and tested for the presence of the integrated transgene.

### 3.3 DNA preparation and screening of recombinant Embryonic Stem (ES) Cell lines

Genomic DNA was prepared from the ES cells by aspirating the medium from each well of the 24 well "Analysis" plate, washing once with 1ml PBS and subsequent addition of 0.5ml lysis buffer (100mM Tris.HCl pH8.5, 5mMEDTA, 0.2% SDS, 200mMNaCl and 100 $\mu$ g ml<sup>-1</sup> Proteinase K). The plate was left to shake slowly on a rotary shaker at room temperature overnight to facilitate lysis and DNA release from the cells. The DNA was precipitated by adding an equal volume of isopropanol, spun, washed in 70% ethanol solution and the precipitate resuspended in approximately 150ml of TE buffer (10mM Tris. HCl, 1mM EDTA , pH 8.0). One microlitre of this DNA was used for subsequent analysis by Polymerase Chain Reaction (PCR) for the presence of the transgene in the ES cell clone. PCR was performed with the primers NS 25 (GGGCAGTCAACAGCTAAAACCT) and NS 26 (TCCAGGGAGCAAAACAACTTCT) using AmpliTaq DNA polymerase (Perkin

ElmerTechnologies). The PCR reactions were carried out on a Robocycler™ (Stratagene) and 30 cycles of DNA amplification at 94° C for 40 s, 54° C for 40 s and 72° C for 90 s to generate a 425 bp amplicon. Greater than 50% of the ES cell clones analysed were positive for the presence of the transgene and were used to establish recombinant ES cell lines from which founder mice could be generated.

### 3.4 Generation of founders and screening of transgenic mice

Chimaeric ("founder", F<sub>0</sub>) mice were generated by blastocyst microinjection of ES cells described above, essentially as described, (Hogan, B., Costatini, F. and Lacy, E., 1986, *Manipulating the mouse embryo*. Cold Spring Harbor Laboratory and, *Gene Targeting-A Practical Approach*, edited by A.L Joyner, 1993, 2002, Oxford University Press. Recipient blastocysts were obtained from C57 BL/6 J females, which had previously been mated with stud C57bl/6 males. Chimaeric mice were identified by the presence of the coat colour marker from the donor ES cell line (chinchilla) against the background of the recipient strain (Black). Chimaeric males were test bred by backcrossing to C57 BL/6 J females to ascertain the contribution of the ES cell line to the germline and to establish transgenic lines. In general, the degree of coat colour chimaerism of a particular chimaera correlated with the degree of germline contribution. Transmission of the Hu/MuICAM-1 transgene was confirmed by PCR analysis, according to the specific assay described above. Subsequently, offspring were bred onto the Balb/c genetic background by successive backcross matings (to N=10) of male transgenic mice to wild type Balb/c females.

### 3.5 Analysis of Chimaeric ICAM-1 Expression

Expression of chimaeric ICAM-1 in transgenic mice was analysed by Western Immunoblotting using human ICAM-1 specific antibodies.

#### 3.5.1 Generation of Purified Human ICAM-1 Specific Antibodies

Antigenic regions of the human ICAM domain were predicted using algorithms within the Lasergene suite of programs. Two regions which are unique to human ICAM (Genpept P05362), and not present in the murine orthologue (Genpept A45815) by extensive BLAST analysis, were chosen as immunogens (see Figure 5). The synthetic peptides SB186 CTPLPKKELLPGNNRKVY and SB187 QTSVSPSKVILPRGC were produced using standard solid phase techniques and analysed using HPLC and MS. The peptides were conjugated to the carrier protein PPD (purified protein derivative of Tuberculin), via the Cys residues, using the cross-linker sulpho-SMCC (Perbio). The resulting conjugates were dissolved in PBS and stored at -20° C until used.

Each peptide-carrier conjugate was used to immunise pairs of female New Zealand White rabbits. Animals were primed by inoculation of ca.100ug conjugate emulsified in Complete Freund's adjuvant at 3 subcutaneous sites. Boosters were given at 3-4 week intervals using incomplete adjuvant. The immune responses of the animals were followed by analysis of test bleeds taken 7 days after each

immunisation. The titres of each antisera was determined using indirect ELISA with microtitre plates coated with free peptide as antigen. After 3 immunisations, all rabbits had achieved a titre of >450,000 by ELISA and samples of the serum were then affinity isolated and tested for cross-reactivity with the holoprotein by immunocytochemistry, immunohistochemistry and immunoblotting. Once satisfactory results were obtained in these assays (after 3-4 immunisations) terminal bleeds were performed.

Serum samples of up to 2ml were diluted 5 fold with PBS and applied to precycled 2ml columns (Sulpholink, Perbio) of appropriate immobilised peptide (2mg). Unbound material was removed by washing with 10-20 volumes of PBS. Specific anti-peptide antibodies were eluted from the columns using 0.1M glycine-HCL pH 2.5 that was neutralised by collecting into 1M Tris pH 8.0. Purified antibodies were dialysed exhaustively into PBS and quantified by measuring absorbance at A280nm. Samples of each antibody were stored at -80C until used, after adding sodium azide as preservative and crystalline BSA as stabiliser. Effective absorption and elution was confirmed in each case by analysis of flow-through and eluted materials using the indirect ELISA.

### 3.5.2 Analysis of Chimaeric ICAM-1 Transgene Expression by Western Immunoblotting

The lung tissues were extracted from mice of approximately 3-6 months of age (N=3 backcross to Balb/c) and a portion of the right lobe taken from male and female transgenic and non-transgenic mice, snap-frozen in liquid nitrogen and stored at -80°C until required. Tissue from each was prepared for, and analysed by Western Immunoblotting. Cell (10 µl) or tissue extracts (50 µg) were pre-treated at 100 °C in 2 x DTT sample buffer without loading dye. Extracts were clarified by brief centrifugation and protein concentrations estimated using the Bradford method by reference to a BSA standard curve (Perbio). The samples were electrophoresed using BioRad Criterion 4-20% gradient gels and resolved proteins transferred to nitrocellulose filters by semi-dry blotting. The efficiency of transfer was judged using Ponceau S stain and then remaining protein binding sites on the blots saturated with 5% dried milk powder (Marvel) dissolved in PBS. Duplicate blots were made and probed with antisera raised to either, HuICAM-1 peptide SB186 (A258) or HuICAM-1 peptide SB187 (A270) at 5 µg/µl in blocking solution containing 0.1% (v.v.) tween20 overnight at 4°C and bound antibodies revealed using anti-rabbit immunoglobulin HRP conjugate followed by ECL detection.

This experimental approach demonstrated that chimaeric ICAM-1 expression was observed in the lung tissue of both male and female transgenic (but not non-transgenic) mice in 50% of the transgenic lines generated. Identical results were obtained on probing with antisera raised against either peptide, thereby providing further validation and confirmation of the data. After probing for chimaeric ICAM-1

expression, the blots were stripped and reprobed using a monoclonal antibody against alpha tubulin. These results confirmed approximately equivalent loadings between the different samples tested. Representative immunoblotting data is shown in Figure 6.

- 5        All publications and references, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference in their entirety as if each individual publication or reference were specifically and individually indicated to be incorporated by reference herein as being fully set forth. Any patent  
10        application to which this application claims priority is also incorporated by reference herein in its entirety in the manner described above for publications and references.



Claims

1. A transgenic non-human animal whose genome comprises a polynucleotide encoding human ICAM-1 domains D1 and D2.
- 5 2. A transgenic non-human animal according to claim 1, wherein said polynucleotide encodes human ICAM-1 domains D1 and D2 and one or more host non-human animal ICAM-1 domains D3, D4 or D5.
- 10 3. A transgenic non-human animal according to claim 2, wherein said polynucleotide encodes human ICAM-1 domains D1 and D2 and host non-human animal ICAM-1 domains D3, D4 and D5.
- 15 4. A transgenic non-human animal according to any of claims 1 to 3, wherein said polynucleotide comprises one or more of the following polynucleotide sequences:
  - 20 (a) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:2;
  - (b) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:3;
  - 25 (c) a polynucleotide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:5;
  - (d) a polynucleotide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:6;
  - 30 (e) a polynucleotide fragment of SEQ ID No:1 (or a sequence with at least 90%, or more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) encoding human ICAM-1 domains D1 and D2; and
  - 35 (f) a polynucleotide sequence encoding a polypeptide fragment of SEQ ID No:4 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) comprising human ICAM-1 domains D1 and D2.
- 40 5. A transgenic non-human animal according to any of claims 1 to 4, whose genome further comprises a regulatory sequence capable of directing expression of said polynucleotide in cells and/or tissues of the respiratory tract.

6. A transgenic non-human animal according to claim 5, wherein said regulatory sequence is a promoter selected from the group consisting of CMV, SV40, human surfactant protein C (SPC) or Clara cell 10KDa secretory (CC10).
- 5 7. A transgenic non-human animal according to any one of claims 1 to 4, which expresses an ICAM-1 polypeptide comprising human ICAM-1 domains D1 and D2.
- 10 8. A transgenic non-human animal according to claim 7, which expresses a chimaeric ICAM-1 polypeptide comprising human ICAM-1 domains D1 and D2.
- 15 9. A transgenic non-human animal according to claim 8, which expresses a chimaeric ICAM-1 polypeptide comprising one or more of the following polypeptide sequences:
  - (a) a polypeptide fragment of SEQ ID No:4 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) comprising human ICAM-1 domains D1 and D2;
  - 20 (b) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:5; and
  - (c) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:6.
- 25 10. A transgenic non-human animal according to claim 9, wherein said chimaeric ICAM-1 polypeptide comprises one or more of host non-human animal ICAM-1 domains D3, D4 and D5.
- 30 11. A transgenic non-human animal according to claim 10, wherein said chimaeric ICAM-1 polypeptide comprises host non-human animal ICAM-1 domains D3, D4, and D5.
- 35 12. A transgenic non-human animal according to any of claims 9 to 11, wherein said chimaeric ICAM-1 polypeptide is expressed in the cells and/or tissues of the respiratory tract.
- 40 13. A transgenic non-human animal according to any of claims 8 to 12, wherein said chimaeric ICAM-1 polypeptide is capable of binding and supporting major group HRV infection.

14. A transgenic non-human animal according to any preceding claim, wherein said animal is a rodent.
- 5 15. A transgenic non-human animal according to any preceding claim, wherein said animal is a mouse or a rat.
16. A transgenic non-human animal according to claim 15, wherein said animal is a mouse.
- 10 17. A transgenic animal according to any of claims 1 to 6, wherein said animal is a mouse and said polynucleotide comprises one or more of the following polynucleotide sequences:
- 15 (a) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:8;
- (b) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:9;
- 20 (c) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99%, or 100% identity to the polynucleotide sequence of SEQ ID No:10;
- 
- 25 (d) a polynucleotide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:11;
- (e) a polynucleotide sequence encoding a polypeptide sequence having at least 90% or more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:12;
- 30 (f) A polypeptide sequence encoding a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99%, or 100% identity to the polypeptide sequence of SEQ ID No:13;
- (g) a polynucleotide fragment of SEQ ID No:7 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) encoding one or more of murine ICAM-1 domains D3, D4 and D5;
- 35 (h) a polynucleotide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polynucleotide sequence of SEQ ID No:14; and
- 40 (i) a polynucleotide encoding a polypeptide having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:15.

18. A transgenic animal according to any of claims 7 to 13, wherein said animal is a mouse and said chimaeric ICAM-1 polypeptide comprises one or more of the following polypeptide sequences:

- 5 (a) a polypeptide fragment of SEQ ID No:7 (or a sequence with at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to it) comprising one or more of murine ICAM-1 domains D3, D4 and D5;
- (b) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:11;
- 10 (c) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:12;
- (d) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity with the polypeptide sequence of SEQ ID No:13; and
- 15 (e) a polypeptide sequence having at least 90%, more preferably 95%, 96%, 97%, 98%, 99% or 100% identity to the polypeptide sequence of SEQ ID No:15.

20 19. A chimaeric transgene comprising a polynucleotide encoding human ICAM-1 domains D1 and D2.

25 20. A chimaeric transgene according to claim 19, wherein said polynucleotide encodes one or more of host non-human animal ICAM-1 domains D3, D4 and D5.

30 21. A chimaeric transgene according to claim 20, wherein said polynucleotide encodes host non-human animal ICAM-1 domains D3, D4 and D5.

22. A chimaeric transgene according to any of claims 19 to 22, wherein said host non-human animal is a rodent, preferably a mouse.

35 23. A chimaeric transgene according to any of claims 19 to 22, further comprising a regulatory sequence capable of directing expression of said polynucleotide in cells and/or tissues of the respiratory tract.

24. A vector comprising the transgene according to any of claims 19 to 23.

40 25. A cell stably transfected or transformed with the transgene according to any of claims 19 to 23.

26. A method of producing the transgenic non-human animal of any of claims 1 to 18.
- 5 27. A method according to claim 26, wherein the transgene according to any of claims 19 to 23 is introduced into non-human animal ES cells using electroporation, retroviral vectors or lipofection for gene transfer.
- 10 28. A method according to claim 27, wherein the non-human transgenic animal is a mouse and the transgene is introduced into mouse ES cells using electroporation, retroviral vectors or lipofection for gene transfer, particularly electroporation.
- 15 29. A method of screening test agents for use in the treatment of a condition associated with or exacerbated by major group HRV infection, the method comprising administering a test agent to a transgenic non-human animal as defined in any one of claims 1 to 18, and evaluating the phenotypic effects.
-

**Figure 1**

**Map of pHuMoICAM-1:  
(Human- Mouse chimeric ICAM1 cDNA in pcDNA3.1+)**




Figure 2






Figure 3

LA-4 Cells

Control




HRV16



LA-4 ICAM-1 Cells

Control



HRV16








Figure 4



HRV16  
LA4 cells



HRV16  
LA4 ICAM-1 cells

**Figure 5**

Details of HuICAM-1 peptides for generation of Rabbit anti-Human ICAM-1 polyclonal antisera





Figure 6

Analysis of Hu/MuICAM-1 expression in lung tissue of ICAM-1 transgenic mice



(F=female; M=Male; += transgenic mouse; - =non-transgenic mouse; A258/A270= immunoblot using polyclonal antisera raised to Human ICAM-1 specific peptides SB186 and SB187 respectively; Ponceau S/Tubulin = Indicates equivalence of protein loading on gel and transfer to membrane;

# SEQUENCE LISTING

## SEQ IQ No:1

gcgccccagt	cgacgctgag	ctcctctgct	actcagagtt	gcaacctcag	cctcgctatg
gctcccagca	gcccccgcc	cgcgctgccc	gcactcctgg	tcctgctcgg	ggctctgttc
ccaggacctg	gcaatgccc	gacatctgtg	tccccctcaa	aagtcctcct	gccccgggga
ggctccgtgc	tggtgacatg	cagcacctcc	tgtgaccagc	ccaagttggt	gggcatagag
accccgttgc	ctaaaaagga	gttgctcctg	cctgggaaca	accggaaggt	gtatgaactg
agcaatgtgc	aagaagatag	ccaaccaatg	tgctattcaa	actgccctga	tgggcagtca
acagctaaaa	ccttcctcac	cgtgtactgg	actccagaac	gggtggaact	ggcaccctc
ccctcttggc	agccagtggg	caagaacctt	accctacgct	gccaggtgga	gggtggggca
ccccgggcca	acctcacctg	ggtgctgctc	cgtggggaga	aggagctgaa	acgggagcca
gctgtggggg	agcccgtga	ggtcacgacc	acggtgctgg	tgaggagaga	tcacctgga
gccaatttct	cgtgccgcac	tgaactggac	ctgcggcccc	aagggtgga	gctgtttgag
aacacctcgg	ccccctacca	gtccagacc	tttgtcctgc	cagcgactcc	cccacaactt
gtcagcccc	gggtcctaga	ggtggacacg	caggggaccg	tggtctgttc	cctggacggg
ctgttccag	tctcggaggc	ccaggtccac	ctggcactgg	gggaccagag	gttgaacccc
acagtcacct	atggcaacga	ctccttctcg	gccaaagcct	cagtcagtgt	gaccgcagag
gacgagggca	cccagcggct	gacgtgtgca	gtaatactgg	ggaaccagag	ccaggagaca
ctgcagacag	tgaccatcta	cagctttccg	gcgcccacg	tgattctgac	gaagccagag
gtctcagaag	ggaccgaggt	gacagtgaag	tgtgaggccc	accctagagc	caaggtgacg
ctgaatgggg	ttccagccca	gccactgggc	ccgagggccc	agctcctgct	gaaggccacc
ccagaggaca	acgggcgcag	cttctcctgc	tctgcaaccc	tggaggtggc	cggccagctt
atacacaaga	accagaccog	ggagcttcgt	gtcctgtatg	gcccccgact	ggacgagagg
gattgtccgg	gaaactggac	gtggccagaa	aattcccagc	agactccaat	gtgccaggct
tgggggaacc	cattgcccga	gtcgaagtgt	ctaaaggatg	gcactttccc	actgcccctc
ggggaatcag	tgactgtcac	togagatcct	gagggcacct	acctctgtcg	ggccaggagc
actcaagggg	aggtcacccg	caaggtgacc	gtgaatgtgc	tctccccccg	gtatgagatt
gtcatcatca	ctgtggtagc	agccgcagtc	ataatgggca	ctgcaggcct	cagcacgtac
ctctataacc	gccagcggaa	gatcaagaaa	tacagactac	aacaggccca	aaaagggacc
cccatgaaac	cgaacacaca	agccacgcct	ccctgaacct	atcccgggac	agggcctctt
cctcggcctt	cccatattgg	tggcagtggg	gccacactga	acagagtgga	agacatatgc
catgcagcta	cacctaccgg	ccctgggacg	ccggaggaca	gggcattgtc	ctcagtcaga
tacaacagca	tttggggcca	tggtacctgc	acacctaaaa	cactaggcca	cgcatctgat
ctgtagtca	atgactaagc	caagaggaag	gagcaagact	caagacatga	ttgatggatg
ttaaagtcta	gctgatgag	aggggaagtg	gtgggggaga	catagcccca	ccatgaggac
atacaactgg	gaaatactga	aacttgctgc	ctattgggta	tgctgaggcc	ccacagactt
acagaagaag	tggccctcca	tagacatgtg	tagcatcaaa	acacaaaggc	ccacacttcc
tgacggatgc	cagcttgggc	actgctgtct	actgacccca	acccttgatg	atatgtattt
attcatttgt	tattttacca	gctattttatt	gagtgtcttt	tatgtaggct	aaatgaacat
aggtctctgg	cctcacggag	ctcccagtc	taatcacatt	caaggtcacc	aggtacagtt
gtacaggttg	tacactgcag	gagagtgcct	ggcaaaaaga	tcaaatgggg	ctgggacttc
tcattggcca	acctgccttt	ccccagaagg	agtgattttt	ctatcggcac	aaaagcacta
tatggactgg	taatggttac	aggttcagag	attacccagt	gaggccttat	tcctcccttc
ccccaaaaac	tgacaccttt	gttagccacc	tccccacca	catacatttc	tgccagtgtt
cacaatgaca	ctcagcggtc	atgtctggac	atgagtgcct	agggaatatg	cccaagctat
gccttgcct	cttgcctgt	ttgcatttca	ctgggagctt	gcactatgca	gctccagttt
cctgcagtga	tcagggtcct	gcaagcagtg	gggaaggggg	cgaaggtatt	ggaggactcc
ctcccagctt	tggaagcctc	atccgcgtgt	gtgtgtgtgt	gtatgtgtag	acaagctctc
gctctgtcac	ccaggctgga	gtgcagtggg	gcaatcatgg	ttcactgcag	tcttgacctt
ttgggctcaa	gtgatectcc	cacctcagcc	tcctgagtag	ctgggaccat	aggctcacia
caccacacct	ggcaaatgtg	atTTTTTTTT	TTTTTccaga	gacgggtct	cgcaacattg
cccagacttc	ctttgtgtta	gttaataaag	ctttctcaac	tgcc	

## SEQ ID No:2

GGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTT  
GTTGGGCATAGAGACCCCGTTGCCTAAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAA  
GGTGTATGAAGTGAAGCAATGTGCAAGAAGATAGCCAACCAATGTGCTATTCAAAGTCCCC  
TGATGGGCAGTCAACAGCT

SEQ ID No:3

GGCAAGAACCTTACCCTACGCTGCCAGGT  
GGAGGGTGGGGCACCCCGGGCCAACCTCACCGTGGTGCTGCTCCGTGGGGAGAAGGAGCT  
GAAACGGGAGCCAGCTGTGGGGGAGCCCGCTGAGGTCACGACCACGGTGTGCTGGTGAGGAG  
AGATCACCATGGAGCCAATTTCTCGTGCCGCACTGAAGTGGACCTGCGG

SEQ ID No:4

mapssprpal pallvllgal fpgpgnaqts vspskvilpr ggsvlvtcst scdqpkllgi  
etplpkell lpgnnrkve lsnvqedsqp mcysncpdgq staktfltv wtpervelap  
lpswqpvgkn ltlrcqvegg apranltvvl lrgekelkre pavgepaevt ttvlvrrdhh  
ganfscrtel dlrrpqqlelf entsapyqlq tfvlpatppq lvsprvlevd tqgtvvcsl  
glfpvseaqv hlalgdqrln ptvtygndsf sakasvsvta edegtqrllc avilgnqsqe  
tlqvtiysf papnviltkp evsegtevtv kceahprakv tlngvpaqpl gpraqlllka  
tpedngrsfs csatlevagq lihknqtrel rvlygprlde rdcpgnwtwp ensqqtpmcq  
awgnplpelk clkdgtfplp igesvtvtrd legtylcrar stqgevtrev tvnvlsprie  
iviitvvaav vimgtaglst ylynrqrkik kyrllqqaqkg tpmkpntqat pp

SEQ ID No:5

GlyGlySerValLeuValThrCysSerThrSerCysAspGlnProLysLe  
uLeuGlyIleGluThrProLeuProLysLysGluLeuLeuLeuProGlyAsnAsnArgLy  
sValTyrGluLeuSerAsnValGlnGluAspSerGlnProMetCysTyrSerAsnCysPr  
oAspGlyGlnSerThrAla

SEQ ID No:6

GlyLysAsnLeuThrLeuArgCysGlnVa  
lGluGlyGlyAlaProArgAlaAsnLeuThrValValLeuLeuArgGlyGluLysGluLe  
uLysArgGluProAlaValGlyGluProAlaGluValThrThrThrValLeuValArgAr  
gAspHisHisGlyAlaAsnPheSerCysArgThrGluLeuAspLeuArg

SEQ ID No:7

atggcttcaa cccgtgccaa gcccacgcta cctctgetcc tggccctggt caccgttgtg  
atccctgggc ctggtgatgc tcaggtatcc atccatccca gagaagcctt cctgccccag  
ggtgggtccg tgcaggtgaa ctgttcttcc tcatgcaagg aggacctcag cctgggcttg  
gagactcagt ggctgaaaga tgagctcgag agtggaacca actggaagct gtttgagctg  
agcgagatcg gggaggacag cagtccgctg tgctttgaga actgtggcac cgtgcagtcg  
tccgettcg ctaccatcac cgtgtattcg tttccggaga gtgtggagct gagacctctg  
ccagcctggc agcaagtagg caaggacctc accctgctg gccacgtgga tgggtggagca  
ccgcggaacc agctctcagc agtgctgctc cgtggggagg agatactgag ccgccagcca  
gtgggtgggc accccaagga cccaaggag atcacattca cggtgctggc tagcagaggg  
gaccacggag ccaatttctc atgccgcaca gaactggatc tcaggccgca agggctggca  
ttgttctcta atgtctccga ggccaggagc ctccggactt tcgatcttcc agctaccatc  
ccaaagctcg acaccctga cctcctggag gtgggcaccc agcagaagtt gttttgctcc  
ctggaaggcc tgtttcctgc ctctgaagct cggatatacc tggagctggg aggccagatg

ccgacccagg agagcacaaa cagcagtgc tctgtgtcag ccactgcctt ggtagagggtg  
actgaggagt tcgacagaac cctgccgctg cgctgcgttt tggagctagc ggaccagatc  
ctggagacgc agaggacctt aacagtctac aacttttcag ctccggtcct gaccctgagc  
cagctggagg tctcggaagg gagccaagta actgtgaagt gtgaagccca cagtgggtcg  
aaggtgggtc ttctgagcgg cgtcgagcct aggccaccca ccccgagggt ccaattcaca  
ctgaatgcc a gctcggagga tcacaaacga agcttctttt gctctgccgc tctggagggtg  
gcgggaaagt tcctgtttta aaaccagacc ctggaaactgc acgtgctgta tggctctcgg  
ctggacgaga cggactgctt ggggaactgg acctggcaag aggggtctca gcagactctg  
aaatgccagg cctgggggaa cccatctcct aagatgacct gcagacggaa ggcagatggt  
gccctgctgc ccatcggggt ggtgaagtct gtcaaacagg agatgaatgg tacatacgtg  
tgccatgcct ttagctccca tgggaatgtc accaggaatg tgtacctgac agtactgtac  
cactctcaaa ataactggac tataatcatt ctggtgccag tactgctggt cattgtgggc  
ctcgtgatgg cagcctctta tgtttataac cgccagagaa agatcaggat atacaagtta  
cagaaggctc agggaggaggc cataaaactc aagggacaag cccacactcc ctga

SEQ ID No:8

GGCACCCAGCAGAAGTTGTTTTG  
CTCCCTGGAAGGCCTGTTTCTGCCTCTGAAGCTCGGATATACCTGGAGCTGGGAGGCCA  
GATGCCGACCCAGGAGAGCACAAACAGCAGTGA CTCTGTGTCAGCCACTGCCTTGGTAGA  
GGTGA CTGAGGAGTTCGACAGAACCCTGCCGCTGCGCTGCGTTTTGGAGCTAGCGGACCA  
G

SEQ ID No:9

GGGAGCCAAGTAACTGTGAAGTGTGAAGCCACAGTGG  
GTCGAAGGTGGTTCTTCTGAGCGGCGTCGAGCCTAGGCCACCCACCCCGCAAGTCCAATT  
CACACTGAATGCCAGCTCGGAGGATCACAAACGAAGCTTCTTTTGCTCTGCCGCTCTGGA  
GGTG

SEQ ID No:10

GAGGGGTCTCAGCAGAC  
TCTGAAATGCCAGGCCTGGGGGAACCCATCTCCTAAGATGACCTGCAGACGGAAGGCAGA  
TGGTGCCCTGCTGCCCATCGGGGTGGTGAAGTCTGTCAAACAGGAGATGAATGGTACATA  
CGTGTGCCATGCCTTTAGCTCC

SEQ ID No:11

GlyThrGlnGlnLysLeuPheCy  
sSerLeuGluGlyLeuPheProAlaSerGluAlaArgIleTyrLeuGluLeuGlyGlyGl  
nMetProThrGlnGluSerThrAsnSerSerAspSerValSerAlaThrAlaLeuValGl  
uValThrGluGluPheAspArgThrLeuProLeuArgCysValLeuGluLeuAlaAspGl  
n

SEQ ID No:12

GlySerGlnValThrValLysCysGluAlaHisSerGl  
ySerLysValValLeuLeuSerGlyValGluProArgProProThrProGlnValGlnPh  
eThrLeuAsnAlaSerSerGluAspHisLysArgSerPhePheCysSerAlaAlaLeuGl  
uVal

SEQ ID No:13

GluGlySerGlnGlnTh  
rLeuLysCysGlnAlaTrpGlyAsnProSerProLysMetThrCysArgArgLysAlaAs  
pGlyAlaLeuLeuProIleGlyValValLysSerValLysGlnGluMetAsnGlyThrTy  
rValCysHisAlaPheSerSer

SEQ ID No:14

ATGGCTCCCAGCAGCCCCCGGCCGCTGCCCCGACTCCTGGTCCTGCT  
CGGGGCTCTGTTCCCAGGACCTGGCAATGCCAGACATCTGTGTCCCCCTCAAAGTCAT  
CCTGCCCCGGGGAGGCTCCGTGCTGGTGACATGCAGCACCTCCTGTGACCAGCCCAAGTT  
GTTGGGCATAGAGACCCCGTTGCCTAAAAGGAGTTGCTCCTGCCTGGGAACAACCGGAA  
GGTGATGAAGTGAAGCAATGTGCAAGAAGATAGCCAACCAATGTGCTATTCAAAGTCCCC  
TGATGGGCAGTCAACAGCTAAAACCTTCCTCACCCTGTACTGGACTCCAGAACGGGTGGA  
ACTGGCACCCCTCCCTCTTTGGCAGCCAGTGGGCAAGAACCTTACCCTACGCTGCCAGGT  
GGAGGGTGGGGCACCCCGGGCCAACCTCACCGTGGTGCTGCTCCGTGGGGAGAAGGAGCT  
GAAACGGGAGCCAGCTGTGGGGGAGCCCGCTGAGGTACAGACCACGGTGCTGGTGAGGAG  
BglI  
AGATCACCATGGAGCCAATTTCTCGTGCCGCACTGAACTGGACCTGCGGCCCAAGGGCT  
GGCATTGTTCTCTAATGTCTCCGAGGCCAGGAGCCTCCGGACTTTCGATCTTCCAGCTAC  
CATCCCAAAGCTCGACACCCCTGACCTCCTGGAGGTGGGCACCCAGCAGAAGTTGTTTTG  
CTCCCTGGAAGGCCTGTTTCCTGCCTCTGAAGCTCGGATATACCTGGAGCTGGGAGGCCA  
GATGCCGACCCAGGAGAGCACAAACAGCAGTGACTCTGTGTGAGCCACTGCCTTGGTAGA  
GGTGACTGAGGAGTTCGACAGAACCCTGCCGCTGCGCTGCGTTTTGGAGCTAGCGGACCA  
GATCCTGGAGACGCGAGGACCTTAACAGTCTACAACCTTTTCAGCTCCTGTCTGACCCT  
GAGCCAGCTGGAGGTCTCGGAAGGGAGCCAAGTAAGTGTGAAGTGTGAAGCCACAGTGG  
GTCGAAGGTGGTTCTTCTGAGCGGCTCGAGCCTAGGCCACCCACCCCGCAAGTCCAATT  
CACACTGAATGCCAGCTCGGAGGATCACAAACGAAGCTTCTTTTGCTCTGCGGCTCTGGA  
GGTGGCGGGAAAGTTCTGTTTAAAAACCAGACCCTGGAAGTGCACGTGCTGTATGGTCC  
TCGGCTGGACGAGACGGACTGCTTGGGGAACTGGACCTGGCAAGAGGGGTCTCAGCAGAC  
TCTGAAATGCCAGGCCTGGGGGAACCCATCTCCTAAGATGACCTGCAGACGGAAGGCAGA  
TGGTGCCCTGCTGCCCATCGGGGTGGTGAAGTCTGTCAAACAGGAGATGAATGGTACATA  
CGTGTGCCATGCCTTTAGCTCCCATGGGAATGTCAACAGGAATGTGTACCTGACAGTACT  
GTACCACCTCTCAAATAACTGGACTATAATCATTCTGGTGCCAGTACTGCTGGTCATTGT  
GGGCCTCGTGATGGCAGCCTCTTATGTTTATAACCGCCAGAGAAAGATCAGGATATACAA  
GTTACAGAAGGCTCAGGAGGAGGCCATAAACTCAAGGGACAAGCCCCACCTCCCTGA

SEQ ID No:15

MetAlaProSerSerProArgProAlaLeuProAlaLeuLeuValLeuLe  
uGlyAlaLeuPheProGlyProGlyAsnAlaGlnThrSerValSerProSerLysValIl  
eLeuProArgGlyGlySerValLeuValThrCysSerThrSerCysAspGlnProLysLe  
uLeuGlyIleGluThrProLeuProLysLysGluLeuLeuLeuProGlyAsnAsnArgLy  
sValTyrGluLeuSerAsnValGlnGluAspSerGlnProMetCysTyrSerAsnCysPr  
oAspGlyGlnSerThrAlaLysThrPheLeuThrValTyrTrpThrProGluArgValGl  
uLeuAlaProLeuProSerTrpGlnProValGlyLysAsnLeuThrLeuArgCysGlnVa  
lGluGlyGlyAlaProArgAlaAsnLeuThrValValLeuLeuArgGlyGluLysGluLe  
uLysArgGluProAlaValGlyGluProAlaGluValThrThrThrValLeuValArgAr  
gAspHisHisGlyAlaAsnPheSerCysArgThrGluLeuAspLeuArgProGlnGlyLe  
uAlaLeuPheSerAsnValSerGluAlaArgSerLeuArgThrPheAspLeuProAlaTh  
rIleProLysLeuAspThrProAspLeuLeuGluValGlyThrGlnGlnLysLeuPheCy  
sSerLeuGluGlyLeuPheProAlaSerGluAlaArgIleTyrLeuGluLeuGlyGlyGl  
nMetProThrGlnGluSerThrAsnSerSerAspSerValSerAlaThrAlaLeuValGl  
uValThrGluGluPheAspArgThrLeuProLeuArgCysValLeuGluLeuAlaAspGl  
nIleLeuGluThrGlnArgThrLeuThrValTyrAsnPheSerAlaProValLeuThrLe

uSerGlnLeuGluValSerGluGlySerGlnValThrValLysCysGluAlaHisSerGly  
ySerLysValValLeuLeuSerGlyValGluProArgProProThrProGlnValGlnPhe  
ThrLeuAsnAlaSerSerGluAspHisLysArgSerPhePheCysSerAlaAlaLeuGlu  
ValAlaGlyLysPheLeuPheLysAsnGlnThrLeuGluLeuHisValLeuTyrGlyPro  
ArgLeuAspGluThrAspCysLeuGlyAsnTrpThrTrpGlnGluGlySerGlnGlnThr  
LeuLysCysGlnAlaTrpGlyAsnProSerProLysMetThrCysArgArgLysAlaAsp  
GlyAlaLeuLeuProIleGlyValValLysSerValLysGlnGluMetAsnGlyThrTy  
rValCysHisAlaPheSerSerHisGlyAsnValThrArgAsnValTyrLeuThrValLeu  
TyrHisSerGlnAsnAsnTrpThrIleIleIleLeuValProValLeuLeuValIleVal  
GlyLeuValMetAlaAlaSerTyrValTyrAsnArgGlnArgLysIleArgIleTyrLys  
LeuGlnLysAlaGlnGluGluAlaIleLysLeuLysGlyGlnAlaProProPro

SEQ ID No:16

ctgtgcctg	cactttgccc	tggtcctcca	atggcttcaa	cccgtgccag	gcccatgctg
cctctgctcc	tggtcctggg	cgccgttggt	atccccgggc	ctgtcgggtgc	tcaggtatcc
atccatccca	cagaagcctt	cctgcctcgg	gggtggatccg	tgacaggtgaa	ctgctcttcc
tcttgcaag	acgagaacct	cgccctgggg	ttggagacta	actggatgaa	agacgaacta
tcgagtggac	acaactggaa	gctcttcaag	ctgagcgaca	ttggggaaga	cagcagacca
ctgtgctttg	agaactgtgg	caccacgcag	tcctcggctt	ctgccacccat	cactgtgtat
tcgttcccag	agcgagtggg	gctggatcct	ctgcccgcct	ggcagcaggt	gggcaagaac
ctcatcctgc	gctgcctggg	ggaaggcgga	gcaccgcgga	cacagctctc	agtagtgctg
ctccgtggga	atgagacact	gagccgccc	gcagtggatg	gggaccccaa	ggagatcaca
ttcacgggtg	tgccagcag	aggcgaccac	ggagccaatt	tctcatgctt	cacagaactg
gacctcaggc	cacaagggct	gtcactgttc	aagaatgtct	cagaggtcag	gcagctccgg
actttcgatc	ttccgactag	ggtcctgaag	ctcgacaccc	ctgacctcct	ggagggtggg
accacgcaga	agttcttgtg	ttccctggaa	ggcctgtttc	ctgcctctga	agctcagata
tacctggaga	tgggaggcca	gatgctgacc	ctggagagca	caaacagcag	agattttgtg
tcagccactg	cctcagtggg	ggtgactgag	aagttggaca	gaacctgca	gctgcgctgt
gttttggagc	tggcggacca	gacctgagg	atggagaaga	ccttgagaat	ctacaacttt
tcagctccca	tcctgacctt	gagccagccg	gaggtctcag	aaggggacca	agtaactgtg
aagtgtgaag	cccacggtgg	ggcacagggt	gtgcttctga	acagtacttc	ccccaggcca
cccacctcac	agggtacttc	ccccaggcca	cccacctcac	agatccaatt	cacagtgaat
gccagcccgg	aggatcacaa	acgacgcttc	ttttgctctg	cggccttgga	ggtgagtggt
aagtccctgt	ttaaaaacca	gaccttgga	ctccatgtgc	tatatggtcc	tcacctggac
aagaaggact	gcttggggaa	ctggacctgg	caagaggggt	ctcagcagac	tcttacatgc
cagccccagg	ggaatccagc	ccctaactctg	acctgcagcc	ggaaagcaga	tgggtgtccc
ctgcctatcg	ggatggtgaa	gtctgtcaaa	cgggagatga	atggtacct	caagtgccgt
gccttttagct	cccgtgggag	tatcaccagg	gacgtgcacc	tgacagtgt	gtacctgat
cagaatacct	gggtcataat	tggtggtgtg	ttggtactga	tcattgctgg	cttcgtgatc
gtggcgctca	tttacacct	ttaccgccag	aggaagatca	ggatatacaa	gttacagaag
gctcaggagg	aggccctaaa	actcaaggta	caagccccgc	ctccctgagc	ccactggaca
ggacacctgc	ctgggccccg	ctgctcttga	acagatcaat	ggacagcatt	tacctctcac
ccacctctc	tggtgtcac	aggacaggac	agtggcctgg	ggatgcatac	ttgtagcctc
aggcctaaga	ggactcggag	gggcaagact	gtgaactcgt	gacctggaca	cacctacagc
ctgggtgggc	tgacgccaag	aaaggctgac	ttccttctct	attacctctg	ctgagggggc
ccctacctta	ggaagggtgtg	atatccggt	gacacaagca	agagaagaaa	aggaacacca
tgcttctct	gacatgggaa	agctgggaca	ctgtcccaa	ctcttggtga	tgtatttatt
aattcagagt	tctgacagtt	atattattg	tacctgtac	agacactaga	ggagtggaca
ggttaacatg	taagttattg	cctagacctt	ggtgaagggg	cacaacagag	tctggggaaa
gatcatacgg	gtttgggctt	ctccacagg	cagggtgctt	tcctcaaaag	agctgatttc
tttcacgagt	catataaata	ctatgtggac	gagcagtggc	cctctgctcg	tagacctctc
tgggaccttc	gcctcctccc	acagcctgga	gtctcccagc	accagcatgg	gtgaccacct
ccccacctac	atacattcct	acctttgttc	ccaatgtcaa	ccacctgccc	taaatatgga
cgctcacctt	tagcagctca	acaatggagt	ctcatgccc	tgaaattatg	gtcaatccct
gcatgcctcc	acccggctcc	acctcaaaga	gaatgcctgg	gagaaaatgt	tccaaccact
tagaagggtc	ctgcaagctg	ttgtgggagg	gtaggcaccc	ctccagcgc	agaagccttt



cotttgaatc aataaagttt ta

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☐ BLACK BORDERS

☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES

☐ FADED TEXT OR DRAWING

☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING

☐ SKEWED/SLANTED IMAGES

☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS

☐ GRAY SCALE DOCUMENTS

☒ LINES OR MARKS ON ORIGINAL DOCUMENT

☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY

☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**